{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:07:21Z","timestamp":1773317241447,"version":"3.50.1"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373090"],"award-info":[{"award-number":["82373090"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103259"],"award-info":[{"award-number":["82103259"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Medical Innovation Research Project","award":["22Y11907600"],"award-info":[{"award-number":["22Y11907600"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A pathological complete response (pCR) following neoadjuvant chemoradiation (CRT) is associated with a favorable prognosis in patients with locally advanced rectal cancer. Patients with metastatic colorectal cancer (mCRC) often receive systemic therapy, and some patients undergo primary tumor resection after preoperative therapy. However, whether oncological outcomes remain favorable in patients with mCRC and pCR in the primary tumor site (ypT0N0M1) following preoperative therapy is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>Patients with mCRC who underwent preoperative therapy followed by primary tumor resection between March 2014 and August 2023, and in whom pCR was confirmed at the primary tumor site, were retrospectively included in this study. The outcome variables investigated were patient demographics, overall survival (OS), and progression-free survival (PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 57 patients who met the inclusion criteria. The median follow-up was 27.1 (range, 7.9-120.6) months. The 2-year PFS and 3-year OS rates in all the patients were 62.2% and 84.5%, respectively. Patients with a primary tumor site in the colon (n\u2009=\u200929) had superior OS (P\u2009=\u20090.039) and a trend toward superior PFS (P\u2009=\u2009.149) compared to those with a primary site in the rectum (n\u2009=\u200928).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with mCRC following preoperative therapy, particularly those with colon cancer, who experienced a pCR in the primary tumor site have a favorable prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag025","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T12:40:37Z","timestamp":1769863237000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-term outcomes following a pathological complete response at the primary tumor site after preoperative therapy in metastatic colorectal cancer"],"prefix":"10.1093","volume":"31","author":[{"given":"Dakui","family":"Luo","sequence":"first","affiliation":[{"name":"Department of Colorectal Surgery, Fudan University Shanghai Cancer Center , Shanghai 200032,","place":["China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai 200032,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Fudan University Shanghai Cancer Center , Shanghai 200032,","place":["China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai 200032,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yikuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Fudan University Shanghai Cancer Center , Shanghai 200032,","place":["China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai 200032,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingguo","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Fudan University Shanghai Cancer Center , Shanghai 200032,","place":["China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai 200032,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunkang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital , Fuzhou 350014,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2354-4735","authenticated-orcid":false,"given":"Xinxiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Fudan University Shanghai Cancer Center , Shanghai 200032,","place":["China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai 200032,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"2026031114024354800_oyag025-B1","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.annonc.2024.06.015","article-title":"Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial","volume":"35","author":"Lin","year":"2024","journal-title":"Ann Oncol"},{"key":"2026031114024354800_oyag025-B2","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1200\/JCO.23.02261","article-title":"Randomized phase II trial of immunotherapy-based total neoadjuvant therapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer (TORCH)","volume":"42","author":"Xia","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026031114024354800_oyag025-B3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/jso.26247","article-title":"Ten-year survival after pathologic complete response in rectal adenocarcinoma","volume":"123","author":"Sell","year":"2021","journal-title":"J Surg Oncol"},{"key":"2026031114024354800_oyag025-B4","doi-asserted-by":"crossref","first-page":"106962","DOI":"10.1016\/j.ejso.2023.06.014","article-title":"Long-term oncologic outcomes and risk factors for distant recurrence after pathologic complete response following neoadjuvant treatment for locally advanced rectal cancer. A nationwide, multicentre study","volume":"49","author":"Cerd\u00e1n-Santacruz","year":"2023","journal-title":"Eur J Surg Oncol"},{"key":"2026031114024354800_oyag025-B5","doi-asserted-by":"crossref","first-page":"105551","DOI":"10.1016\/j.esmoop.2025.105551","article-title":"Neoadjuvant chemotherapy with FOLFOXIRI for high-risk relapsed locally advanced colon cancer: a single-arm phase II trial","volume":"10","author":"Zhou","year":"2025","journal-title":"ESMO Open."},{"key":"2026031114024354800_oyag025-B6","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1200\/JCO.23.01889","article-title":"Neoadjuvant chemotherapy with oxaliplatin and fluoropyrimidine versus upfront surgery for locally advanced colon cancer: the randomized, phase III OPTICAL trial","volume":"42","author":"Hu","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026031114024354800_oyag025-B7","first-page":"233","article-title":"Colorectal cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2026031114024354800_oyag025-B8","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer: a review","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA"},{"key":"2026031114024354800_oyag025-B9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00384-018-3202-8","article-title":"Current status of immunotherapy in metastatic colorectal cancer","volume":"34","author":"Wrobel","year":"2019","journal-title":"Int J Colorectal Dis"},{"key":"2026031114024354800_oyag025-B10","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1001\/jamaoncol.2023.3323","article-title":"Neoadjuvant immune checkpoint inhibitor therapy for localized deficient mismatch repair colorectal cancer: a review","volume":"9","author":"Emiloju","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026031114024354800_oyag025-B11","first-page":"10","article-title":"Neoadjuvant treatment for surgically resectable metastatic colorectal cancer","volume":"30","author":"Al-Hajeili","year":"2016","journal-title":"Oncology (Williston Park)"},{"key":"2026031114024354800_oyag025-B12","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/bjs\/znab342","article-title":"Neoadjuvant immunotherapy in primary and metastatic colorectal cancer","volume":"108","author":"Kanani","year":"2021","journal-title":"Br J Surg"},{"key":"2026031114024354800_oyag025-B13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jnci\/djaa052","article-title":"Pathological tumor response following immune checkpoint blockade for deficient mismatch repair advanced colorectal cancer","volume":"113","author":"Ludford","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2026031114024354800_oyag025-B14","first-page":"341","article-title":"Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature","volume":"21","author":"Sehdev","year":"2016","journal-title":"Discov Med"},{"key":"2026031114024354800_oyag025-B15","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.2147\/OTT.S298333","article-title":"Complete pathologic response after concurrent treatment with pembrolizumab and radiotherapy in metastatic colorectal cancer: a case report","volume":"14","author":"Yang","year":"2021","journal-title":"Onco Targets Ther"},{"key":"2026031114024354800_oyag025-B16","first-page":"140","article-title":"Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma","volume":"7","author":"Duffy","year":"2008","journal-title":"Clin Colorectal Cancer."},{"key":"2026031114024354800_oyag025-B17","doi-asserted-by":"crossref","first-page":"e73-7","DOI":"10.1016\/j.clinre.2015.06.004","article-title":"Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: a case report from the FFCD 1201 trial","volume":"39","author":"Pernot","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag025\/66719710\/oyag025.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/4\/oyag025\/66719710\/oyag025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/4\/oyag025\/66719710\/oyag025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T18:04:35Z","timestamp":1773252275000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag025\/8455776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag025","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,2,3]]},"article-number":"oyag025"}}